Tysabri (Natalizumab): Update of Healthcare Professional Information
Links shared publicly online about this topic.
- 1,404total visits
Tysabri (Natalizumab): Update of Healthcare Professional Information
fda.gov —
View full resource at fda.gov
Tags: Healthcare, FDA, Tysabri
Most Recently Shared on February 5, 2010 at 5:49 pm By:
FDA adds new info to MS drug Tysabri label about rare, potentially fatal brain infection that's affected 31 users http://bit.ly/ab4qvb
Also Shared By:
FDA Alert: Tysabri (natalizumab): Update of Healthcare Professional Information
drugs.com — “FDA Alert: Tysabri (natalizumab): Update of Healthcare Professional Information” View full resource at drugs.com
Most Recently Shared on April 23, 2011 at 11:06 pm By:
FDA Alert - Update of Healthcare Professional Information: Tysabri (natalizumab) - http://bit.ly/dV3ExV
FDA Alert: Tysabri (Natalizumab): Update of Healthcare Professional Information
drugs.com — “FDA Alert: Tysabri (Natalizumab): Update of Healthcare Professional Information” View full resource at drugs.com
Most Recently Shared on February 7, 2010 at 10:06 pm By:
FDA Alert - Revisions to Prescribing Information for Tysabri (natalizumab) - http://bit.ly/b2C46Z
Tysabri labeling to include safety information on risk of progressive multifocal leukoencephalopathy - MPR
empr.com — “The FDA has notified healthcare professionals and patients that the risk of developing progressive multifocal leukoencephalopathy (PML) increases with the number of Tysabri (natalizumab, from Biogen Idec) infusions received.” View full resource at empr.com
Most Recently Shared on February 5, 2010 at 6:44 pm By:
MPR News: Tysabri labeling to include safety information on risk of progressive multifocal leukoencephalopathy: Th... http://bit.ly/9G7EQr
Advertisement
eyeonfda
@eyeonfda
FDA MedWatch updates on Tysabri - http://ow.ly/14hlb - PML Risk increases with number of infusions.
1 year ago...